Biosergen AB (8N10) Stock Statistics & Valuation Metrics

Biosergen AB has a market cap or net worth of €1.28M. The enterprise value is €77.44.

Biosergen AB has 2,348,232 shares outstanding. The number of shares has decreased by -2.65% in one year.

Biosergen AB’s return on equity (ROE) is -3.47 and return on invested capital (ROIC) is -351.89%.

The current PE Ratio of Biosergen AB is ―. Biosergen AB’s PEG ratio is -0.02.

In the last 12 months, Biosergen AB had revenue of 0.00 and earned -40.82M in profits. Earnings per share was -17.38.

In the last 12 months, operating cash flow was -30.97M and capital expenditures 0.00, giving a free cash flow of -30.97M billion.

Biosergen AB pays an annual dividend of ―, resulting in a dividend yield of ―

Biosergen AB upcoming earnings date is Aug 19, 2026, TBA (Confirmed).

Biosergen AB as a current ratio of 2.46, with Debt / Equity ratio of 0.00%

In the past 12 months, Biosergen AB has paid 0.00 in taxes.

Biosergen AB EV to EBITDA ratio is -1.90, with an EV/FCF ratio of -2.10.

Biosergen AB has €15.37M in cash and marketable securities with €0.00 in debt, giving a net cash position of €15.37M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Biosergen AB is ―, which is 11.43% higher than the current price. The consensus rating is ―